FCGR3A and breast cancer: Compared with RES120, MGAH22 showed increased maximum lysis and lower effective concentration for 50% lysis (EC50) with CD16A F/F or V/F effector cells (purified NK cells) against JIMT-1 breast cancer cells (Figure 3a-e).